RECKITT BENCKIS/S (OTCMKTS:RBGLY) Earns “Overweight” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) in a research report released on Wednesday morning, The Fly reports.

Other research analysts have also recently issued research reports about the company. Credit Suisse Group reiterated a neutral rating on shares of RECKITT BENCKIS/S in a research note on Wednesday. Royal Bank of Canada reaffirmed an underperform rating on shares of RECKITT BENCKIS/S in a research report on Wednesday. Berenberg Bank reissued a buy rating on shares of RECKITT BENCKIS/S in a research report on Friday, July 10th. Morgan Stanley reaffirmed an overweight rating on shares of RECKITT BENCKIS/S in a report on Monday, June 15th. Finally, Zacks Investment Research upgraded shares of RECKITT BENCKIS/S from a hold rating to a buy rating and set a $18.00 price target on the stock in a report on Thursday, May 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $18.00.

Shares of RBGLY opened at $20.41 on Wednesday. The company has a quick ratio of 0.42, a current ratio of 0.56 and a debt-to-equity ratio of 0.91. The stock has a market cap of $72.40 billion, a P/E ratio of 22.68 and a beta of 0.71. The business’s 50 day moving average price is $18.94 and its 200-day moving average price is $16.93. RECKITT BENCKIS/S has a 52 week low of $12.76 and a 52 week high of $21.00.

RECKITT BENCKIS/S Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Recommended Story: Dividend Reinvestment Plan (DRIP)

The Fly

Analyst Recommendations for RECKITT BENCKIS/S (OTCMKTS:RBGLY)

Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.